What is a step-by-step flow chart for selecting antibiotics to treat resistant Gram-negative bacilli infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Antibiotic Selection Algorithm for Resistant Gram-Negative Bacilli Infections

For resistant GNB infections, initiate treatment based on the specific pathogen and resistance mechanism identified, prioritizing newer β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Enterobacterales (CRE), ceftolozane-tazobactam for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA), and ampicillin-sulbactam combinations for carbapenem-resistant Acinetobacter baumannii (CRAB), with combination therapy reserved for severe infections. 1

Step 1: Identify the Pathogen and Resistance Pattern

Obtain cultures immediately and perform rapid susceptibility testing including:

  • Species identification (Enterobacterales vs. Pseudomonas vs. Acinetobacter)
  • Carbapenemase detection (KPC, NDM, OXA-48, VIM, IMP)
  • Metallo-β-lactamase (MBL) testing - this is critical as it completely changes treatment options 2
  • MIC determination for available antibiotics

Critical pitfall: Do not wait for full susceptibility results to start empirical therapy in severe infections, but adjust immediately once results are available.

Step 2: Assess Infection Severity and Site

Severe/High-Risk Infections include:

  • Septic shock or hemodynamic instability
  • Ventilator-associated pneumonia (VAP)
  • Bloodstream infections (BSI)
  • Central nervous system infections

Non-severe infections:

  • Uncomplicated urinary tract infections
  • Localized skin/soft tissue infections without systemic signs

Step 3: Pathogen-Specific Treatment Algorithm

For Carbapenem-Resistant Enterobacterales (CRE)

If MBL-negative (KPC, OXA-48):

  • First choice: Meropenem-vaborbactam for BSI caused by KPC-producing organisms 3
  • Alternative: Ceftazidime-avibactam 1, 2
  • Alternative: Imipenem-relebactam 2

If MBL-positive (NDM, VIM, IMP):

  • First choice: Cefiderocol 2
  • Alternative: Ceftazidime-avibactam + aztreonam (for intra-abdominal infections add metronidazole) 3

For severe CRE infections, add a second active agent:

  • Fosfomycin (particularly for CRKP) 4
  • Aminoglycoside if susceptible
  • High-dose extended-infusion meropenem if MIC ≤8 mg/L 4

For Carbapenem-Resistant Pseudomonas aeruginosa (CRPA)

If susceptible to ceftolozane-tazobactam:

  • First choice: Ceftolozane-tazobactam 1, 2

If resistant to ceftolozane-tazobactam:

  • First choice: Ceftazidime-avibactam 1
  • Alternative: Imipenem-relebactam 1
  • For MBL-producing strains: Cefiderocol 2

For severe CRPA pneumonia:

  • Add aerosolized colistin or aminoglycosides 3
  • Consider combination with fosfomycin for neurological infections 3

For severe/high-risk CRPA infections:

  • Use two in vitro active drugs from: polymyxins, aminoglycosides, or fosfomycin 1

For non-severe CRPA infections:

  • Monotherapy with the most active agent is acceptable 1

For Carbapenem-Resistant Acinetobacter baumannii (CRAB)

If sulbactam-susceptible:

  • First choice: Ampicillin-sulbactam (for HAP/VAP) 1

If sulbactam-resistant:

  • Polymyxin (colistin or polymyxin B) if susceptible 1
  • High-dose tigecycline if susceptible 1

Avoid: Cefiderocol for CRAB (conditional recommendation against) 1

For severe CRAB infections:

  • Combination therapy: Ampicillin-sulbactam + colistin for BSI 3
  • Use two active agents from: polymyxin, aminoglycoside, tigecycline, sulbactam combinations 1

Do NOT use:

  • Polymyxin-meropenem combination (strong recommendation against) 1
  • Polymyxin-rifampin combination (strong recommendation against) 1

Exception: If meropenem MIC ≤8 mg/L, consider high-dose extended-infusion carbapenem in combination 1

Step 4: Dosing Optimization

Implement therapeutic drug monitoring (TDM) for:

  • Polymyxins (strongly recommended) 4
  • Aminoglycosides 4
  • High-dose β-lactams 4

Extended infusion strategies:

  • Meropenem: 3-hour infusion for CRE if MIC ≤8 mg/L 4
  • Piperacillin-tazobactam: continuous infusion with loading dose 3

Monitor renal function closely - avoid combining polymyxins with other nephrotoxic or ototoxic drugs 4

Step 5: Pan-Resistant Organisms

For pan-resistant CR-GNB (resistant to all standard agents including polymyxins):

  • Use the antibiotic with the lowest MIC relative to breakpoints 1
  • Consider double or triple combination therapy
  • Consult infectious diseases specialist immediately

Step 6: De-escalation Strategy

Once susceptibility results available:

  • Narrow to the most appropriate single agent if organism is susceptible and patient is improving
  • Continue combination therapy only if severe infection or high risk of resistance emergence
  • Reassess daily for de-escalation opportunities

Critical Implementation Points

Combination therapy is strongly recommended when:

  • Polymyxin-based treatment is required (moderate-quality evidence supports combination over monotherapy) 4
  • Severe/high-risk infections regardless of pathogen 1, 4
  • Limited treatment options available

Antimicrobial synergy testing may inform combination selection but should not delay treatment 4

Common pitfall: Polymyxin dosing confusion - ensure correct conversion:

  • 1 million U = 80 mg CMS = 33 mg CBA
  • Polymyxin B: 1 mg = 10,000 U 4

References

2
Research

Antibiotic Treatment of Severe Infections with Multiresistant Bacteria.

Deutsches Arzteblatt international, 2026

Related Questions

What antibiotic regimen is recommended for resistant Gram‑negative bacilli infections based on the infected organ site and drug penetration?
Should antipseudomonal and MRSA coverage be restarted after infectious disease discontinued vancomycin, switched piperacillin‑tazobactam to ampicillin‑sulbactam, and the transthoracic echocardiogram was negative?
What is the appropriate empiric antibiotic coverage for Gram-negative cocco-bacilli infections?
What empiric antibiotics should be given to a patient needing broad‑spectrum intravenous coverage for Gram‑negative rods, anaerobes, and possible Pseudomonas, considering β‑lactam allergy and MRSA risk?
What alternative antibiotics can be used for a patient with an IgE‑mediated allergy to piperacillin‑tazobactam (Zosyn) to provide broad‑spectrum Gram‑negative (including Pseudomonas) coverage?
Which medications increase lipoprotein(a) levels?
What are the recommended dosing regimens for 5% and 25% albumin infusions in adults and children?
What is the recommended rasburicase dose for hyperuricemia and is dose adjustment needed in patients with hepatic impairment?
Can I take Maxalt (rizatriptan) and tadalafil together?
What are the Philippine clinical practice guidelines for diagnosing and managing dengue infection?
What are the primary factors contributing to the recent rise in mortality in Chad?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.